Report

The Stem Cell Manufacturing Market size is estimated at USD 17.03 billion in 2025, and is expected to reach USD 31.33 billion by 2030, at a CAGR of 12.96% during the forecast period (2025-2030).

The COVID-19 pandemic had significantly impacted the stem cell manufacturing market compared to other markets as stem cell-based therapies were suggested to treat COVID-19. Several companies and universities are involved in research studies associated with stem cells. For instance, as per the article published in January 2022 in BMC journal, stem cell therapy and stem cell-derived organoid models received greater emphasis as a new treatment and research method for COVID-19. To better understand the process of SARS-CoV-2 cardiomyocyte-specific infection, several researchers used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC CMS) as a model. In the current scenario, stem cell manufacturing gained a lot more attention due to the wide applications such as pluripotent stem cells used to treat disease forming the basis for future regenerative medicine using stem cells. Due to the surge in technological developments in stem cell synthesis and preservation, it is also projected that the market for stem cell manufacturing is likely to expand in the coming years.

The major factors attributing to the market's growth include the technological advancements in stem cell manufacturing and preservation and growing public awareness about the therapeutic potency of stem cell products. For instance, as per the article published in September 2022 in PubMed, stem cell therapy involving in vitro and in vivo studies is shown to be safe and efficacious in treating various diseases. As per the same source, stem cell treatment seeks to restore or repair damaged organs and congenital malformations using human stem cells such as embryonic stem cells (ESCs), adult stem cells (ASCs), and induced pluripotent stem cells (iPSCs).

Further, product launches, company expansion, and research center launches are anticipated to drive the growth of the market over the forecast period. For instance, in September 2021, STEMCELL Technologies launched human pluripotent stem cell (hPSC) characterization and banking services in partnership with WiCell, making it easier for pluripotent stem cell researchers to achieve critical yet often overlooked steps. Additionally, in October 2022, COST Association celebrated Stem Cell Awareness Day highlighting a network of researchers working to foster a greater understanding of stem cell research and potential applications for millions of people suffering from incurable diseases and injuries.

Thus, the rise in research studies of stem cell therapy, the increase in product launches, and the surge in awareness regarding the importance of stem cell therapy drive the growth of the market over the forecast period. However, the popularity of alternative procedures is a major drawback for the market.

Stem Cell Manufacturing Market Trends

Stem Cell Banking Segment is Likely to Witness a Significant Growth in the Stem Cell Manufacturing Market Over the Forecast Period

A stem cell bank is a provision that stores stem cells developed from amniotic fluid for future use. Stem cell samples in private banks are stored specifically for use by the individual from whom such cells have been collected, and the banking costs are paid by the person. The sample can later be recovered or used only by that individual or, in many cases, by their first-degree blood relatives. The studied segment is anticipated to witness growth owing to the factors such as a rise in launches of stem cell banks globally, an increase in awareness regarding the importance of preserving stem cells.

In addition, the establishment of stem cell banks across the world will contribute significantly to the market's growth. For instance, in September 2021, LifeCell International Pvt. Ltd received an investment of INR 225 crore (USD 27.2 million) from OrbiMed Asia Partners IV in return for a minority stake, which was likely to enable the company to make a foray into adjacent new categories, such as fertility health and cell-based therapeutics.

The major factor driving the segment's growth is the increasing public demand for cord blood stem cell banking and rising awareness regarding the prospective advantages of stem cell preservation. Moreover, several government and private agencies are collaborating to address the common issues associated with stem cell ma manufacturing and processing, improving the working on stem cell banks, thereby driving the segment growth. For instance, in September 2021, STEMCELL Technologies launched human pluripotent stem cell (hPSC) characterization and banking services in partnership with WiCell. These services, offered through STEMCELL's Contract Assay Services division, provide researchers with comprehensive cell quality assessments and enable them to generate cell banks using standardized practices.

Thus, with the rise in research studies of stem cell therapy, and the increase in initiatives and funding for establishing stem cell banks, the studied segment is anticipated to witness significant growth over the forecast period.

North America is Anticipated to Hold a Significant Share in the Market Over the Forecast Period

North America is expected to hold a significant share of the overall market throughout the forecast period. The market growth is due to the presence of key players, high concentration of stem cell research in the region, mounting public-private funding and grants to support the clinical evaluation of stem cells for various applications, robust research infrastructure, and growing public awareness of the therapeutic potency of stem cells. For instance, in April 2022, Canada's Stem Cell Network (SCN) launched IGNITE 2022-2025, its three-year strategic plan funded by the Government of Canada through a USD 45 million Budget 2021 commitment. This strategic plan, IGNITE 2022-2025, is built on three core pillars: research, training, and knowledge mobilization. Each is vital to SCN as they work to position Canadian-based scientists and expertise at the forefront of regenerative medicine (RM) globally.

Furthermore, a rise in the number of approvals partnerships relating to stem cell therapy is expected to drive the market's growth. For instance, in March 2021, Vertex Pharmaceuticals received the FDA grant as a fast-track designation to VX-880, a human stem cell-derived therapy for patients with Type 1 diabetes. VX-880 is a first-in-class, allogeneic, fully differentiated islet cell therapy designed to regulate glucose levels by restoring a patient's pancreatic islet cell function, including insulin production.

Moreover, in November 2022, ExCellThera Inc. completed the patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera's most advanced investigational drug, combines the proprietary molecule UM171 and an optimized culture system to produce unique UM171-expanded stem cell transplants, and it also enables the use of small cord blood units without compromising engraftment. The trials across the different phases show positive outcomes.

Thus, with the rise in research studies of stem cell therapy, and the increase in initiatives and funding by key players and the government, North America is anticipated to hold a significant share of the market over the forecast period.

Stem Cell Manufacturing Industry Overview

The stem cell manufacturing market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are Becton, Dickinson and Company, Fujifilm Holdings Corporation (Cellular Dynamics), Lonza Group, Stemcell Technologies, Merck Group, Thermo Fisher Scientific, and Pluristem Therapeutics Inc.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support